



J Tradit Complement Med. 2019 Apr; 9(2): 138–142.

PMCID: PMC6435946

Published online 2018 May 3.

PMID: [30963048](https://pubmed.ncbi.nlm.nih.gov/30963048/)

doi: 10.1016/j.jtcme.2017.10.005: 10.1016/j.jtcme.2017.10.005

Clinical study of effectiveness and safety of CELcomplex® containing Cucurbita Pepo Seed extract and Flax and Casuarina on stress urinary incontinence in women

Andrea Gažová,^{a,*} Simona Valášková,^b Viera Žufková,^b Ana M. Castejon,^c and Ján Kyselovič^{b,d}

^aInstitute of Pharmacology and Clinical Pharmacology, Faculty of Medicine in Bratislava, Comenius University, Slovakia

^bDepartment of Pharmacology and Toxicology, Faculty of Pharmacy in Bratislava, Comenius University, Slovakia

^cDepartment of Pharmaceutical Sciences, College of Pharmacy Nova South Eastern University, USA

^dDepartment of Internal Medicine, Faculty of Medicine in Bratislava, Comenius University, Slovakia

Andrea Gažová: andrea.gazova@fmed.uniba.sk

*Corresponding author. Faculty of Medicine Comenius University, Institute of Pharmacology and Clinical Pharmacology, Špitalská 24, Bratislava, 813 72, Slovakia. andrea.gazova@fmed.uniba.sk

Received 2016 Dec 7; Revised 2017 Sep 21; Accepted 2017 Oct 6.

Copyright © 2017 Center for Food and Biomolecules, National Taiwan University. Production and hosting by Elsevier Taiwan LLC.

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Abstract

Aim

The safety and effectiveness of a preparation containing a mix of Cucurbita Pepo Seed extract, Equisetum arvense and Linum usitatissimum - Flax A (CELcomplex®) on stress urinary incontinence (SUI) was evaluated in female patients recruited from 20 urological and gynaecological outpatient clinics in Slovakia.

Methods

A total of 86 women aged from 32 to 88 with SUI (grade 1 = 44, grade 2 = 42) were enrolled in the study and followed-up for six weeks (point 1) and twelve weeks (point 2). The primary outcome of the study was evaluated by changes in day-time and nocturnal urinary frequency (bathroom visits) and urinary incontinence episodes (leaks). Also, adverse events were quantified as well as the self-perceived effectiveness of the treatment. Research Ethics Board approval was obtained for this study.

Results

After 12 weeks of treatment there was a 30% (grade 1 SUI, $p < 0.01$), and 35% (grade 2 SUI, $p < 0.01$) improvement in urinary incontinence episodes, a 40% (grade 1 SUI, $p < 0.01$) and 26% (grade 2 SUI, $p < 0.01$) improvement in day-time urination frequency and 64% (grade 1 SUI, $p < 0.01$) and 54% (grade 2 SUI, $p < 0.01$) improvement in nocturnal urinary frequency. Reported side effects were: headache (3.5%), flatulence (4.1%) and gastrointestinal discomfort (3%). A total of 89.4 % of women in the study reported


no side effects from this therapy and 97% acknowledged improvement of symptoms.

Conclusion

This clinical study demonstrated that a 12 week treatment with a mix of Cucurbita Pepo Seed extract, Equisetum arvense and Linum usitatissimum - Flax A (CELcomplex®) is highly effective on stress urinary incontinence (SUI) with minimum adverse events. Further studies may be needed in order to determine the effectiveness and efficacy of this phytotherapy in other populations.

Keywords: Stress urinary incontinence – SUI, Pumpkin seed, Women

Graphical abstract



Abbreviations

SUI stress urinary incontinence
 UI urinary incontinence
 ICS The International Continence Society
 SD standard deviation
 OAB overactive bladder
 GIT-D gastrointestinal discomfort

1. Introduction

The International Continence Society (ICS) defines stress urinary incontinence (SUI) as the complaint of any involuntary leakage, which is associated with increased abdominal pressure and insufficient urethral

sphincter mechanism.³² The main symptom of stress urinary incontinence is the involuntary loss of urine on exertion, sneezing or coughing.

Epidemiological research has revealed several factors associated with urinary incontinence in women. It is caused by obesity, aging, childbirth³² and by a weakening of the bladder sphincter and pelvic floor muscles.¹⁰ Modifiable risk factors have not been investigated to the same extent, and several of the studies that do address such factors do not control adequately for confounders.¹² In women, risk factors for SUI include multiple or complex vaginal deliveries, high infant birth weight, a history of hysterectomy, and physiological changes related to the transition to postmenopause. Smoking, a high body mass index, and constipation are also associated with an increased risk of SUI.^{2, 7, 8, 14, 27, 28}

Urinary incontinence affects almost 50% of middle-aged and older women and significantly impacts quality of life and accounts for more than \$30 billion in annual direct costs in the United States.²⁵ There is a clear dose-response effect of weight on urinary incontinence, with each 5-unit increase in body mass index associated with a 20%–70% increase in risk of urinary incontinence.³¹ Former and current heavy smoking (more than 20 cigarettes per day) is associated with any degree of incontinence while severe incontinence was weakly associated with smoking regardless of the number of cigarettes.¹² Physical activity is a modifiable risk factor with a potential for both positive and negative effects on SUI. The proportion of women reporting incontinence disorder increased incrementally with age since roughly 7% of women between ages 20 and 39 report moderate or severe incontinence, and over 23% of women between ages 60 and 69 suffer from this condition.^{21, 22}

No medications have been approved for the treatment of SUI in the U.S and only one - duloxetine (Cymbalta, Eli Lilly) have been approved in Europe. Duloxetine, a dual serotonin–norepinephrine reuptake inhibitor is indicated only for the treatment of depression and neuropathic pain in the U.S.⁸ Duloxetine is believed to influence neurotransmitters on the pudendal nerve. As a result, urethral sphincter contractions are strengthened, and the increased urethral closure forces prevent urine leakage.^{18, 26, 33} In clinical trials, duloxetine has reduced incontinence episodes by 50% or more and has increased the quality of life in women with SUI. Side effects leading to discontinuation included dry mouth, fatigue, nausea, constipation, and hyperhidrosis. In studies, treatment-related nausea was noted in up to 40% of patients; in most of these patients, nausea occurred early during treatment, was transient, and of mild to moderate severity.^{16, 3, 30, 23}

The seeds and oil from pumpkin seeds have been used for many years for the relief of difficulties associated with an enlarged prostate gland and micturition problems related to irritable bladder.¹⁷ The pumpkin seeds yield approximately 50% oil, (mostly linoleic and oleic acid and tocopherol), but the main active constituents are sterols (avenasterol, spinasterol) and sterol (sitosterol, stigmasterol).¹ The advantage of pumpkin seeds treatment arises from its tonic influence on the bladder and sphincter relaxation (EMA/HMPC/136022/2010). Pumpkin seed extract has beneficial activity in two ways: one on the hormonal level by inhibiting 5-alpha reductase an enzyme involved in hormone metabolism, resulting in anabolic and muscle strengthening effects; and a direct muscle relaxing effect resulting in a decreased urination frequency of the bladder.²⁴ Cucurbita pepo has many other indications approved by the European Medicine Agency (EMA/HMPC/136022/2010) such as benign prostatic hyperplasia, strength bladder function and enlarged prostate. The Equisetum arvense is traditionally used globally in urinary tract diseases. The Linum usitatissimum has a long history of medicinal use and its main effects are laxative, expectorant and inflammation of urinary organs among others.

The aim of the present study was to investigate the efficacy a 12 weeks treatment with CELcomplex® (a mix of Cucurbita Pepo Seed extract, Equisetum arvense and Linum usitatissimum - Flax A) on urinary incontinence episodes (daytime and nocturnal frequency of urination) and its safety (adverse events) in women with a diagnosis of stress incontinence grade I and II.

2. Materials and methods

22/10/2021, 11:31

Frequency improvement of urinary incontinence episodes, day time and nocturnal urinary frequency.

Urinary incontinence episodes, diurnal and nocturnal urinary frequency was captured using a questionnaire at weeks 6 and 12 during treatment. The baseline values (before treatment) for frequency of urinary incontinence episodes (leaks), day time and nocturnal urinary frequencies was compared to the average values after six and twelve weeks of treatment. The number of incontinence episodes was significantly reduced from baseline levels by 19 % and 20% in grade 1 and grade 2 groups respectively after 6 weeks of treatment ($p < 0.05$) (Table 2). After week 12, the frequency of urinary incontinence episodes further decreased by 30 and 35 % compared to baseline in groups 1 and 2 respectively ($p < 0.01$). Moreover, as shown in Table 2, daytime and nocturnal urinary frequency also showed a statistically significant reduction from baseline at week 6 in the grade 1 SUI group (22% and 39% respectively in grade 1 SUI, $p < 0.05$). However, in the grade 2 SUI group, the reduction in daytime and nocturnal urinary frequency was not statistically significant at week 6. After 12 weeks of treatment, both groups experienced a significant reduction in both daytime and nocturnal urinary frequencies (40% and 64% respectively for grade 1 SUI and 26 and 54% respectively for grade 2 SUI, $p < 0.01$).

3.1. Safety and self-perceived efficacy

Adverse events after treatment with the mix of Cucurbita Pepo Seed extract, Equisetum arvense and Linum usitatissimum - Flax A (CELcomplex®) were captured in a questionnaire at week 12. The most common adverse events in both groups were headache (3.5%), flatulence (4.1%) and gastrointestinal discomfort (GIT-D) (2.9 %). The results are shown in the Table 3. A total of 89.4 % of women in the study reported no side effects during the 12 weeks of treatment.

A total of 97 % of participating women in the study reported a self-perceived improvement on incontinence episodes and day time and nocturnal urinary frequency (Table 3). There was no significant difference between groups. The clinical study showed the efficacy and the safety of treatment with CELcomplex®.

4. Discussion

The objective of this clinical study was to determine the effectiveness and safety of CELcomplex® containing Cucurbita Pepo Seed Extract, Flax and Casuarina on Stress Urinary Incontinence in women. As previously described, one of the major risk factors is age. In our clinical study we had two groups of stress incontinence women (grade 1 mean age 51 ± 12 vs. grade 2 mean age 56 ± 11 years). Danforth et al.⁷ had in their study mean age 44.8 and self-reported incontinence was highly prevalent - 43% of women reported leaking urine at least once a month. On the other side the incidence of UI is highest in Caucasians (7.3/100 person-years), followed by Asians (5.7/100 person-years) and African-Americans (4.8/100 person-years).⁸

A in other studies, higher body mass index is generally considered a risk factor for incontinence, and has been confirmed in cross-sectional studies in middle aged women. Among 14,070 women aged 45 to 50 in the Women's Health Australia project, obese women (body mass index 30–40 kg/m²) had an increased risk (RR = 2.05, 95% CI 1.70–2.46) of any incontinence compared with body mass index < 20 kg/m².⁵ These results are consistent with our results. In our clinical study women had an average body mass index of more than 27 kg/m². A strong correlation between body mass index and intra-abdominal pressure ($r = 0.76$, $P < 0.0001$) and intravesical pressure ($r = 0.71$, $P < 0.0001$) was found by Noblett et al.,²⁰ suggesting that obesity may cause a chronic state of increased pressure that stresses the pelvic floor.

Moreover, childbearing is an established incontinence risk factor.¹³ Chiarelli et al.⁵ observed similar odds of leaking urine among women with one childbirth (adjusted OR = 1.58, 95% CI 1.29–1.93) and women with two childbirths. The women that participated in our study had a 1.7 averaged childbirths in the grade 1 group and 2.0 in the grade 2 group. However in our clinical study we included women without childbirth (8% together). We collected information on the mode of delivery – no women with Cesarean-section.

Hannestad et al.¹² demonstrated that heavy smoking and intake of tea is related to incontinence while

increasing hours of low intensity of physical activity is associated with decreased risk of incontinence. In our study non-smokers (grade 1 89% non-smoker vs. grade 2 94% non-smoker) had stress incontinence. However, a limitation of this study is that we did not obtain information about smoking history from the women participating in the study.

After menopause, women with osteoporosis are more likely to have urinary incontinence than are women with healthy bones. LaRusso¹⁵ in the study found that therapy including pelvic floor muscle training dramatically reduces urine leakage. On the baseline in our study 24% were Kegel⁴ exercise training, after 6th week the number of exercise women was increased to 42% and after 12th week there were training 47% of women. Oestrogen deficiency is an etiologic factor in the pathogenesis of several conditions.²⁹ Oestrogen deficiency was not definitely defined in our research; we had more than 50% of women with normal functional oestrogen.

Limited pharmacological treatment for this condition is available. In Europe only Duloxetine is available while in the United States there are not approved drugs for this disorder. Phytotherapeutic compounds are largely used in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia due to low side-effect profiles and costs, high level of acceptance by patients and a low rate of dropout. Cucurbita pepo's mechanism of action is mediated by a decrease in aromatase activity and 5-alpha-reductase.⁶ The advantage of pumpkin seeds treatment arises from its tonic influence on the bladder and sphincter relaxation.⁹ The pumpkin seeds yield approximately 50% oil, but the main active constituents are sterols.¹

We identified only a few interventional studies using pumpkin seed in urinary incontinence.^{10, 19, 24, 32} A study of 39 incontinent females (aged 52–86 years) using pumpkin seed and soy isoflavone extracts (EFLA[®] 940) was conducted over a six-week period. The objective was to evaluate the effects on daytime and nocturnal urinary frequency and number of daily incontinent episodes. After six weeks, the nocturnal urinary frequency was improved by 39% (from 3.3 to 2.0), the daytime urinary frequency was improved by 16% (from 8.0 to 6.7) and the number of incontinent episodes was lowered by 79% (from 7.3 to 1.5).²⁴ In another study conducted in 50 incontinent women (aged 35–84 years) using the same pumpkin seed-soy extract supplement for six weeks, the overall improvement in all incontinent events was 67%.³² However, there is a significant limitation in these two studies using pumpkin seed and soy isoflavone extracts, since the characteristics of participating women is missing, making hard to identify women that may respond or not to this phytotherapy.

In our study we confirmed 30% improvement in incontinence episodes frequency in women with stress urinary incontinent grade 1 and 35% improvement in grade 2 after a 12-week treatment. The daytime urinary frequency significantly improved by 40% in grade 1 and 26% in grade 2. The nocturnal urinary frequency was also improved by about 64% in the grade 1 group and about 54% in the grade 2 group. In the present study we found a much better improvement in daytime incontinence frequency (difference 17%) and during the night (difference 18%) compared to using pumpkin seed and soy isoflavone extracts (EFLA[®] 940). However, in that study²⁴ a striking 79% improvement was found for incontinence episodes, nevertheless, women had a more severe baseline (7.3/day) episodes compared to our population.

To note, no adverse effects for pumpkin seeds were registered in the study by Friederich et al.¹¹ Only mild gastrointestinal complaints (diarrhoea, nausea, vomiting), in no more than 4% of the patients, were reported.⁶ In our clinical study we found mild gastrointestinal discomfort, flatulence and headache in 10.6% of the volunteer women participating in this study while over 89% did not report side effects from these preparation. When the self-reported efficacy was analysed, 97% of women were satisfied with the CELcomplex[®] treatment for stress urinary incontinence. In all women with SUI grade 1 a subjective improvement was found as early as they reached the 6th week and it was maintained throughout the study. In women with SUI grade 2, the subjective improvement was 88% after 6 weeks of treatment, but all women found this therapy effective by the 12th week. This difference can be explained by the fact that grade 2 SUI is a more severe condition and may take longer to be relieved with this therapy. Some limitations should be considered. All information on frequency urinary incontinence, day time and

nocturnal urinary frequency were self-reported with questionnaires. Also, this study did not have a control group.

5. Conclusion

This clinical study demonstrated that a 12 week treatment with a mix of Cucurbita Pepo Seed extract, Equisetum arvense and Linum usitatissimum - Flax A (CELcomplex®) is significantly effective on stress urinary incontinence (SUI) with minimum adverse events. Further studies are needed to determine the effectiveness and efficacy of this phytotherapy in other populations compared with Kegel's exercise group without CELcomplex®.

Author declaration template

We wish to confirm that there are no known conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome.

Footnotes

Peer review under responsibility of The Center for Food and Biomolecules, National Taiwan University.

References

1. Akjhis Toshihiro. Sterols of the cucurbitaceae. *Phytochemistry*. 1987;6:1693–1700.
2. Bump R.C., McClish D.M. Cigarette smoking and pure genuine stress incontinence of urine: a comparison of risk factors and determinants between smokers and nonsmokers. *Am J Obstet Gynecol*. 1994;2:579–582. [PubMed: 8116716]
3. Bump, Richard C. Long-term efficacy of duloxetine in women with stress urinary incontinence. *BJU Int*. 2008;2:214–218. [PubMed: 18422764]
4. Burgio Larsen Kathran, Robinson Courtland J., Engel Bernarn T. The role of biofeedback in Kegel exercise training for stress urinary incontinence. *Am J Obstet Gynecol*. 1986;1:58–64. [PubMed: 3946505]
5. Chiarelli Pauline., Brown Wendy., McElduff Patrick. Leaking urine: prevalence and associated factors in Australian women. *Neurourol Urodyn*. 1999;18:567–577. [PubMed: 10529705]
6. Damiano Rocco. The role of Cucurbita pepo in the management of patients affected by lower urinary tract symptoms due to benign prostatic hyperplasia: a narrative review. *Arch Ital Urol Androl*. 2016;88:2. [PubMed: 27377091]
7. Danforth, Kim N. Risk factors for urinary incontinence among middle-aged women. *Am J Obstet Gynecol*. 2006;2:339–345. [PMCID: PMC1363686] [PubMed: 16458626]
8. DeMaagd, George A., Davenport Timothy C. Management of urinary incontinence. *Pharm Ther*. 2012;37(6):345–361H. [PMCID: PMC3411204] [PubMed: 22876096]
9. EMA/HMPC/136022/2010. Assessment report on Cucurbita pepo L., semen. http://www.ema.europa.eu/docs/en_GB/document_library/Herbal_HMPC_assessment_report/2011/10/WC500116579.pdf.
10. Faloon W. Life Extension Magazine; 2008. A Breakthrough in the Relief of Overactive Bladder and Urinary Incontinence. <http://www.lifeextension.com/magazine/2008/11/pumpkin-seed-relieves-overactive-bladder-urinary-incontinence/page-01>
11. Friederich M., Theurer C., Schiebel-Schlosser G. Prosta Fink Forte-Kapseln in der Behandlung der benignen Prostatahyperplasie. Eine multizentrische Anwendungsbeobachtung an 2245 Patienten. *Forsch Komplementärmed Res Complement Med*. 2004;4:200–204. [PubMed: 11025395]
12. Hannestad, Yngvild S. Are smoking and other lifestyle factors associated with female urinary

- incontinence. The Norwegian EPINCONT Study. *BJOG Int J Obstet Gynaecol*. 2003;3:247–254. [PubMed: 12628262]
13. Hunskaar S. Epidemiology and natural history of urinary incontinence. *Int Urogynecol J*. 2000;5:301–319. [PubMed: 11052566]
14. Kemmer H. Obstructive sleep apnea syndrome is associated with overactive bladder and urgency incontinence in men. *Sleep*. 2009;2:271–275. [PMCID: PMC2635592] [PubMed: 19238815]
15. LaRusso Laurie. Women-only cardiac rehabilitation. *Nurs Womens Health*. 2016;3:244. doi: 10.1016/j.nwh.2016.04.019. [CrossRef: 10.1016/j.nwh.2016.04.019]
16. Lin, Alex, Tong-Long Duloxetine versus placebo for the treatment of women with stress predominant urinary incontinence in Taiwan: a double-blind, randomized, placebo-controlled trial. *BMC Urol*. 2008;8:2. [PMCID: PMC2266773] [PubMed: 18221532]
17. Manal Abdel-Rhman, K. Effect of pumpkin seed (*Cucurbita pepo* L.) diets on benign prostatic hyperplasia (BPH): Chemical and morphometric evaluation in rats. *World J Chem*. 2006;1:33–40.
18. Millard R.J. Duloxetine vs placebo in the treatment of stress urinary incontinence: a four-continent randomized clinical trial. *BJU Int*. 2004;3:311–318. [PubMed: 14764128]
19. Nishihira Mie. Pumpkin seed oil extracted from *Cucurbita maxima* improves urinary disorder in human overactive bladder. *J Tradit Complement Med*. 2014;1:72. [PMCID: PMC4032845] [PubMed: 24872936]
20. Noblett K.L., Jensen J.K., Ostergard D.R. The relationship of body mass index to intra-abdominal pressure as measured by multichannel cystometry. *Int Urogynecol J*. 1997;6:323–326. [PubMed: 9609328]
21. Nygaard I.E. Lifetime physical activity and female stress urinary incontinence. *Am J Obstet Gynecol*. 2015;1:40. e1-40.e10. [PMCID: PMC4485543] [PubMed: 25640047]
22. Nygaard I. Prevalence of symptomatic pelvic floor disorders in US women. *JAMA*. 2008;11:1311–1316. [PMCID: PMC2918416] [PubMed: 18799443]
23. Schagen, van Leeuwen J.H. Efficacy and safety of duloxetine in elderly women with stress urinary incontinence or stress-predominant mixed urinary incontinence. *Maturitas*. 2008;2:138–147. [PubMed: 18547757]
24. Sogane H., Terado T. 2001. Open Clinical Study of Effects of Pumpkin Seed Extract/Soybean Germ Extract Mixture-containing Processed Food on Nocturia; pp. 1–17.
25. Subak, Leslee L., Richter, Holly E., Hunskaar, Steinar Obesity and urinary incontinence: epidemiology and clinical research update. *J Urol*. 2009;6:2–7. [PMCID: PMC2866035] [PubMed: 19846133]
26. Pantazis, Konstantinos Freeman, Robert M. Investigation and treatment of urinary incontinence. *Curr Obstet Gynaecol*. 2006;6:344–352.
27. Thom D.H., van den Eeden S.K., Brown J.S. Evaluation of parturition and other reproductive variables as risk factors for urinary incontinence in later life. *Obstet Gynecol*. 1997;6:983–989. [PubMed: 9397116]
28. Thom D.H., Brown J.S. Reproductive and hormonal risk factors for urinary incontinence in later life: a review of the clinical and epidemiologic literature. *J Am Geriatr Soc*. 1998;11:1411–1417. [PubMed: 9809764]
29. Thüroff, Joachim W. EAU guidelines on urinary incontinence. *Eur Urol*. 2011;3:387–400. [PubMed: 21130559]
30. Vella Maria., Duckett Jonathan., Basu Maya. Duloxetine 1 year on: the long-term outcome of a cohort of women prescribed duloxetine. *Int Urogynecol J Pelvic Floor Dysfunct*. 2008;7:961–964. [PubMed:

18231697]

31. Whitcomb, Emily L., Subak, Leslee L. Effect of weight loss on urinary incontinence in women. *Open Access J Urol*. 2011;3:123–132. [PMCID: PMC3818946] [PubMed: 24198645]

32. Yanagisawa E. Study of effectiveness of mixed processed food containing Cucurbita pepo seed extract and soybean seed extract on stress urinary incontinence in women. *Jpn J Med Pharm Sci*. 2003;14:313–322.

33. Zinner N.R., Koke S.C., Viktrup L. Pharmacotherapy for stress urinary incontinence: present and future options. *Drugs*. 2004;14:1503–1516. [PubMed: 15233589]

Figures and Tables

Table 1

Characteristics of women in the clinical study.

	Grade 1 SUI (n = 44)	Grade 2 SUI (n = 42)
Age (years)	51 ± 12	56 ± 11*
Body mass index (kg/m ²)	27 ± 5.8	28 ± 4.9
Number of childbirth	1.7 ± 1.0	2.00 ± 0.9
Smoker (%)	89% none/11% yes	94% none/6% yes
Menopause (%)	71% none/29% yes	56% none/44% yes*

Values are expressed as average ± standard deviation (SD), *p < 0.05.

Table 2

The characteristics of the improvement of urinary incontinence in the clinical study.

	Grade1			Grade 2		
	Baseline	Week 6 (Improvement %)	Week 12 (Improvement %)	Baseline	Week 6 (Improvement %)	Week 12 (Improvement %)
Daily frequency of incontinence episodes (leaks)	2.9 ± 0.4	2.4 ± 0.2* (19 %)	2.1 ± 0.2** (30 %)	3.9 ± 0.4	3.1 ± 0.2* (20 %)	2.5 ± 0.2** (35 %)
Daytime urinary frequency (times to the bathroom)	4.6 ± 0.4	3.6 ± 0.3* (22 %)	2.7 ± 0.2** (40 %)	4.5 ± 0.5	4.0 ± 0.2 (12 %)	3.4 ± 0.2** (26 %)
Nocturnal urinary frequency (times to the bathroom)	2.3 ± 0.4	1.5v0.2* (39 %)	0.8 ± 0.2** (64 %)	2.51 ± 0.34	2.1 ± 0.2 (16 %)	1.2 ± 0.1** (54 %)

Values are expressed as average ± standard deviation (SD), (*p < 0.05), (**p < 0.01).

Table 3

The Adverse events after treatment with CELcomplex® in the clinical study.

Adverse events	Grade 1		Grade 2		Total (average)
	6 week (%)	12 week (%)	6 week (%)	12 week (%)	
Headache	4.5	4.5	2.4	2.4	3.5
Flatulence	4.5	4.5	4.8	2.4	4.1
GIT-D	4.5	0.0	2.4	4.8	2.9
no side effects	86.5	91.0	90.0	90.0	89.4
Benefits	100.0	100.0	88.0	100.0	97.0

Values are expressed as average, the benefits are epressed as percentage (*p < 0.05), (**p < 0.01).

Articles from Journal of Traditional and Complementary Medicine are provided here courtesy of **Elsevier**